Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Price, Forecast & Analysis

USA - NASDAQ:ORGO - US68621F1021 - Common Stock

4.25 USD
+0.02 (+0.47%)
Last: 10/31/2025, 4:30:02 PM
4.25 USD
0 (0%)
After Hours: 10/31/2025, 4:30:02 PM

ORGO Key Statistics, Chart & Performance

Key Statistics
Market Cap539.15M
Revenue(TTM)429.53M
Net Income(TTM)-15587000
Shares126.86M
Float67.44M
52 Week High6.71
52 Week Low2.61
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.05
PEN/A
Fwd PE13.44
Earnings (Next)11-06 2025-11-06/amc
IPO2016-12-02
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ORGO short term performance overview.The bars show the price performance of ORGO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

ORGO long term performance overview.The bars show the price performance of ORGO in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ORGO is 4.25 USD. In the past year, price increased by 52.16%.

ORGANOGENESIS HOLDINGS INC / ORGO Daily stock chart

ORGO Latest News, Press Relases and Analysis

ORGO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.59 385.18B
AMGN AMGEN INC 13.68 160.66B
GILD GILEAD SCIENCES INC 14.63 148.64B
VRTX VERTEX PHARMACEUTICALS INC 25.12 109.11B
REGN REGENERON PHARMACEUTICALS 14.48 69.08B
ALNY ALNYLAM PHARMACEUTICALS INC 350.8 59.78B
ARGX ARGENX SE - ADR 61.77 50.39B
INSM INSMED INC N/A 40.08B
ONC BEONE MEDICINES LTD-ADR 5.01 34.10B
NTRA NATERA INC N/A 27.30B
BNTX BIONTECH SE-ADR N/A 24.98B
BIIB BIOGEN INC 9.22 22.62B

About ORGO

Company Profile

ORGO logo image Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 869 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

Company Info

ORGANOGENESIS HOLDINGS INC

85 Dan Rd

Canton MASSACHUSETTS 02021 US

CEO: Gary S. Gillheeney Sr.

Employees: 869

ORGO Company Website

ORGO Investor Relations

Phone: 17815750775

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you describe the business of ORGANOGENESIS HOLDINGS INC?

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 869 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.


What is the current price of ORGO stock?

The current stock price of ORGO is 4.25 USD. The price increased by 0.47% in the last trading session.


Does ORGANOGENESIS HOLDINGS INC pay dividends?

ORGO does not pay a dividend.


What is the ChartMill technical and fundamental rating of ORGO stock?

ORGO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists ORGO stock?

ORGO stock is listed on the Nasdaq exchange.


What is the analyst forecast for ORGO stock?

8 analysts have analysed ORGO and the average price target is 8.16 USD. This implies a price increase of 92% is expected in the next year compared to the current price of 4.25.


Can you provide the number of employees for ORGANOGENESIS HOLDINGS INC?

ORGANOGENESIS HOLDINGS INC (ORGO) currently has 869 employees.


ORGO Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ORGO. When comparing the yearly performance of all stocks, ORGO is one of the better performing stocks in the market, outperforming 82.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ORGO Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ORGO. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ORGO Financial Highlights

Over the last trailing twelve months ORGO reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -225% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.38%
ROE -4.32%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-350%
Sales Q2Q%-22.44%
EPS 1Y (TTM)-225%
Revenue 1Y (TTM)-4.2%

ORGO Forecast & Estimates

8 analysts have analysed ORGO and the average price target is 8.16 USD. This implies a price increase of 92% is expected in the next year compared to the current price of 4.25.

For the next year, analysts expect an EPS growth of -136% and a revenue growth 4.04% for ORGO


Analysts
Analysts85
Price Target8.16 (92%)
EPS Next Y-136%
Revenue Next Year4.04%

ORGO Ownership

Ownership
Inst Owners55.08%
Ins Owners31.49%
Short Float %16.47%
Short Ratio16.48